Real-time Estimate
Cboe Europe
06:31:14 2024-07-04 am EDT
|
5-day change
|
1st Jan Change
|
269.2
SEK
|
+2.28%
|
|
+0.90%
|
+42.93%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,689
|
4,945
|
2,823
|
5,191
|
12,243
|
17,298
|
-
|
-
|
Enterprise Value (EV)
1 |
1,607
|
4,602
|
2,638
|
4,989
|
12,076
|
17,036
|
16,809
|
16,489
|
P/E ratio
|
-10.5
x
|
-45.1
x
|
-32.8
x
|
-75.9
x
|
50.3
x
|
130
x
|
64.5
x
|
36.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
0.39%
|
-
|
Capitalization / Revenue
|
10.9
x
|
27.3
x
|
13.3
x
|
15.8
x
|
20.7
x
|
20.1
x
|
14.4
x
|
11.2
x
|
EV / Revenue
|
10.3
x
|
25.4
x
|
12.4
x
|
15.2
x
|
20.4
x
|
19.8
x
|
14
x
|
10.7
x
|
EV / EBITDA
|
-10.7
x
|
-46.7
x
|
-32.7
x
|
-77.3
x
|
867
x
|
108
x
|
51.2
x
|
27.1
x
|
EV / FCF
|
-9.54
x
|
-44.7
x
|
-30.4
x
|
-99.4
x
|
-633
x
|
116
x
|
64.3
x
|
49.2
x
|
FCF Yield
|
-10.5%
|
-2.24%
|
-3.29%
|
-1.01%
|
-0.16%
|
0.86%
|
1.56%
|
2.03%
|
Price to Book
|
13.6
x
|
12.4
x
|
10.6
x
|
19.3
x
|
22.6
x
|
25.6
x
|
19.2
x
|
-
|
Nbr of stocks (in thousands)
|
51,956
|
63,723
|
64,162
|
64,521
|
65,056
|
65,721
|
-
|
-
|
Reference price
2 |
32.50
|
77.60
|
44.00
|
80.45
|
188.2
|
263.2
|
263.2
|
263.2
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
155.5
|
180.9
|
212.9
|
328.8
|
591.1
|
859
|
1,200
|
1,545
|
EBITDA
1 |
-150.4
|
-98.56
|
-80.67
|
-64.54
|
13.93
|
158.4
|
328.4
|
609
|
EBIT
1 |
-158.1
|
-98.56
|
-80.67
|
-64.54
|
13.93
|
152.3
|
321
|
598.5
|
Operating Margin
|
-101.67%
|
-54.5%
|
-37.89%
|
-19.63%
|
2.36%
|
17.73%
|
26.75%
|
38.74%
|
Earnings before Tax (EBT)
1 |
-158.3
|
-99
|
-81.84
|
-64.69
|
15.75
|
152.7
|
322
|
597
|
Net income
1 |
-161.1
|
-101.4
|
-85.53
|
-68.17
|
245
|
133.4
|
267.6
|
474
|
Net margin
|
-103.58%
|
-56.07%
|
-40.18%
|
-20.73%
|
41.45%
|
15.53%
|
22.3%
|
30.68%
|
EPS
2 |
-3.100
|
-1.720
|
-1.340
|
-1.060
|
3.740
|
2.020
|
4.083
|
7.200
|
Free Cash Flow
1 |
-168.5
|
-102.9
|
-86.84
|
-50.19
|
-19.08
|
146.8
|
261.6
|
335
|
FCF margin
|
-108.36%
|
-56.91%
|
-40.79%
|
-15.26%
|
-3.23%
|
17.08%
|
21.8%
|
21.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
92.62%
|
79.67%
|
55.01%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
109.99%
|
97.75%
|
70.68%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
1.020
|
-
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
61.4
|
66.34
|
74.6
|
84.62
|
103.2
|
119.7
|
140.4
|
158.2
|
172.7
|
184.4
|
200
|
220.1
|
246.9
|
263.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.77
|
-16.46
|
-14.9
|
-13.94
|
-19.28
|
0.768
|
5.952
|
14.87
|
-7.658
|
32.29
|
38.7
|
49.2
|
66.7
|
80.7
|
Operating Margin
|
-35.46%
|
-24.8%
|
-19.97%
|
-16.47%
|
-18.68%
|
0.64%
|
4.24%
|
9.4%
|
-4.43%
|
17.51%
|
19.35%
|
22.35%
|
27.01%
|
30.66%
|
Earnings before Tax (EBT)
|
-22.05
|
-16.67
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-24.2
|
-16.37
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-39.42%
|
-24.68%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/4/22
|
7/14/22
|
10/27/22
|
2/16/23
|
4/27/23
|
7/13/23
|
10/26/23
|
2/15/24
|
4/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
81.7
|
343
|
185
|
201
|
167
|
262
|
489
|
809
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-168
|
-103
|
-86.8
|
-50.2
|
-19.1
|
147
|
262
|
335
|
ROE (net income / shareholders' equity)
|
-80%
|
-38.8%
|
-25.7%
|
-25.5%
|
60.2%
|
24.2%
|
32.8%
|
37%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.390
|
6.260
|
4.140
|
4.170
|
8.310
|
10.30
|
13.70
|
-
|
Cash Flow per Share
|
-
|
-
|
-1.300
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.23
|
2.66
|
3.42
|
2.23
|
0.82
|
8
|
7.12
|
14
|
Capex / Sales
|
2.72%
|
1.47%
|
1.6%
|
0.68%
|
0.14%
|
0.93%
|
0.59%
|
0.91%
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Last Close Price
263.2
SEK Average target price
297.7
SEK Spread / Average Target +13.10% Consensus |
1st Jan change
|
Capi.
|
---|
| +41.23% | 1.65B | | +3.79% | 95.71B | | +6.58% | 41.64B | | -13.20% | 32.7B | | +77.57% | 28.65B | | -16.02% | 15.38B | | -8.17% | 12.97B | | -12.49% | 11.47B | | +162.44% | 9.92B | | -54.92% | 9.07B |
Biopharmaceuticals
|